Antimicrobial polymer modifications to reduce microbial bioburden on endotracheal tubes and ventilator associated pneumonia

Barnes, Megan; Feit, Corbin; Grant, Trudy-Ann; Brisbois, Elizabeth J.

doi:10.1016/j.actbio.2019.04.042

Cited by 33 publications

(36 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Endotracheal intubation increases the chances of VAP 6–20 folds (Raad et al, 2011), increasing by 3% per day during the first 5 days of ventilation, and by 2% during days 5 through 10 (May et al, 2014; Pneumatikos, Dragoumanis, & Bouros, 2009; Raad et al, 2011). Accounting for 86% of nosocomial pneumonia cases, VAP is one of the most common hospital‐acquired infections (HAIs), increasing mortality rates, hospital stay, and hospital costs (Barnes, Feit, Grant, & Brisbois, 2019; Koenig & Truwit, 2006; May et al, 2014; Mietto, Pinciroli, Patel, & Berra, 2013). To contract VAP, microorganisms must reach the sterile lower respiratory tract and adhere to the mucosa to begin colonization (Safdar et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

“…However, both of these additions have proven to be ineffective in preventing the spread of bacteria to the lower trachea and have the potential to damage the trachea (Inglis, Millar, Jones, & Robinson, 1989; Mietto et al, 2013). Additional prevention attempts have included various surface modifications to ETTs such as silver‐coated (Barnes et al, 2019; Olson, Harmon, & Kollef, 2002) and gentamicin‐containing hydrogel‐coated ETTs (Barnes et al, 2019; Jones, McCoy, Andrews, McCrory, & Gorman, 2015). Currently, silver‐coated ETTs are the only commercially approved antimicrobial ETTs in the United States.…”

Section: Introductionmentioning

confidence: 99%

“…Additional prevention attempts have included various surface modifications to ETTs such as silver-coated (Barnes et al, 2019;Olson, Harmon, & Kollef, 2002) and gentamicin-containing hydrogel-coated ETTs (Barnes et al, 2019;Jones, McCoy, Andrews, McCrory, & Gorman, 2015). Currently, silver-coated ETTs are the only commercially approved antimicrobial ETTs in the United States.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

S‐Nitroso‐N‐acetylpenicillamine impregnated endotracheal tubes for prevention of ventilator‐associated pneumonia

Homeyer

Singha

Goudie

et al. 2020

Biotech & Bioengineering

View full text Add to dashboard Cite

The chances of ventilator‐associated pneumonia (VAP) increases 6–20 folds when an endotracheal tube (ETT) is placed in a patient. VAP is one of the most common hospital‐acquired infections and comprises 86% of the nosocomial pneumonia cases. This study introduces the idea of nitric oxide‐releasing ETTs (NORel‐ETTs) fabricated by the incorporation of the nitric oxide (NO) donor S‐nitroso‐N‐acetylpenicillamine (SNAP) into commercially available ETTs via solvent swelling. The impregnation of SNAP provides NO release over a 7‐day period without altering the mechanical properties of the ETT. The NORel‐ETTs successfully reduced the bacterial infection from a commonly found pathogen in VAP, Pseudomonas aeruginosa, by 92.72 ± 0.97% when compared with the control ETTs. Overall, this study presents the incorporation of the active release of a bactericidal agent in ETTs as an efficient strategy to prevent the risk of VAP.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

S‐Nitroso‐N‐acetylpenicillamine impregnated endotracheal tubes for prevention of ventilator‐associated pneumonia

Homeyer

Singha

Goudie

et al. 2020

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…Prophylactic approaches by altering the surface of ETTs to prevent the growth and establishment of bacteria have exhibited promising results. Besides, surface modifications with bacteriostatic properties or active coatings that possess a bactericidal effect have been proven effective [34]. VAP can occur through impairment of cough and mucociliary clearance, accumulation above and leaking around the cuff of contaminated secretions, or increased bacterial binding to the surface of the bronchial epithelium.…”

Section: Resultsmentioning

confidence: 99%

Unmasking the Current Scenario of Indian Biomedical Devices Industry: Ventilators being the Heart of the Discussion

Pramanik

Karmakar

Mukherjee

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The Indian Biomedical Device Industry has been growing at an unprecedented rate, but several hindrances need to be acknowledged in offering access to quality, budget-friendly medical devices in India. This article explores the current loopholes of the Indian biomedical device industry along with the proposal of various innovative solutions, with emphasis on ventilators. Methods An online survey with the help of Google forms was conducted from 1st November to 25th December 2020, addressing the problems of the Indian medical device industry (MDI) along with probable solutions. The survey also provides a glimpse into the complications aroused from the frequent use of ventilators during COVID-19 outburst, along with possible measures. Results According to the survey, 51.6%, 46.5%, 55.7%, and 47.5% of respondents have agreed to 'Stringent laws and implementation,' 'Safety testing and strict regulations,' 'Unfavorable duty structure,' and 'Reducing tax rate on domestic manufacturers,' as a possible solution to advance the implementation of ISO 13485 and ISO 10651, implementation of ISO 14971, the probable cause of limitations of Indian MDI, possible measure to overcome limitations of Indian MDI, respectively. 46.7%, 47.5%, 46.2%, and 44.6% of respondents have agreed to 'Surgical decompression,' 'Nebulized and broad-spectrum antibiotics,' 'PEEP,' and 'Adopting lung protective ventilation strategies' as possible solutions to treat various ventilator complications, respectively. Conclusion The study briefs about the people's perception of the Indian MDI as well as on the ventilator complications. The results complied with our hypothesis as the majority of the respondents have agreed with almost all the probable solutions in both the sections given by us as options.

show abstract

“…et al[57] reported a 2-log reduction in bacterial counts after 50 h of cultivation on a PVC polymer surface with 0.15 -0.25 µm thick silver film. In our study, we improved the antibacterial effect of hCQDs/PDMS after only 30 s of plasma treatment by 1log (S. aureus).…”

mentioning

confidence: 99%

Increasing the effectivity of the antimicrobial surface of carbon quantum dots-based nanocomposite by atmospheric pressure plasma

Kováčová

Bodík

Mičušík

et al. 2020

Clinical Plasma Medicine

View full text Add to dashboard Cite

Antimicrobial polymer modifications to reduce microbial bioburden on endotracheal tubes and ventilator associated pneumonia

Cited by 33 publications

References 159 publications

S‐Nitroso‐N‐acetylpenicillamine impregnated endotracheal tubes for prevention of ventilator‐associated pneumonia

S‐Nitroso‐N‐acetylpenicillamine impregnated endotracheal tubes for prevention of ventilator‐associated pneumonia

Unmasking the Current Scenario of Indian Biomedical Devices Industry: Ventilators being the Heart of the Discussion

Increasing the effectivity of the antimicrobial surface of carbon quantum dots-based nanocomposite by atmospheric pressure plasma

Contact Info

Product

Resources

About